



pharmaceuticals ltd.

Regd.&Corporate Office :
Plot No. 19-111, Road No. 71,
Opp. Bharatiya Vidya Bhavan Public School,
Jubilee Hills Hyderabad - 500 096. A.P. INDIA,
Tel : +91-40-6628 8888, Fax : +91-40-2355 1402

By Email/Courier

February 11, 2014

Bombay Stock Exchange Limited
Floor 25, P.J. Towers
Dalal Street
Mumbai-400 001.

National Stock Exchange of India Ltd.
Exchange Plaza, Bandra-Kurla Complex
Bandra (E), Mumbai-400 001.

Scrip Code : 532815

Symbol :SMSPHARMA

Dear Sirs,

Sub: Out-come of the Board Meeting held on 11.02.2014.


We have to inform you that, in our Board Meeting held on 11.02.2014 the Board has taken the following decision.


“Considered and approved the Un-audited Financial Results for the quarter ended 31st December, 2013 with Limited Review Report under Clause 41 of the Listing Agreement.”

A copy of the Un-audited Financial Results for the quarter ended 31st December, 2013 with Limited Review Report is enclosed herewith for your information and record.

Please take the same on your record.

Yours faithfully,
For SMS Pharmaceuticals Limited


Ramesh Babu Potluri
Chairman & Managing Director



Encl: a/a

S.No.	Particulars	(Rs. In Lacs)				
		Quarter Ended		9 Months Ended		Year Ended
		31-12-2013 (Unaudited)	31-12-2012 (Unaudited)	31-12-2013 (Unaudited)	31-12-2012 (Unaudited)	
1	Income from Operations (a) Net sales/Income from Operations (b) Other Operating Income	12,566.51 1,187.23	12,213.57 6,771.56	33,640.32 1,886.53	18,117.81 334.54	23,993.38 239.28
2	Total Income from Operations (net)	13,753.74	12,893.55	35,526.85	18,452.35	24,232.66
3	Expenses (a) Cost of materials consumed (b) Purchases of stock-in-trade (c) Changes in inventories of finished goods stock-in-progress and stock-in trade (d) Employee benefit expenses (e) Depreciation and amortisation expenses (f) Other expenses	8,707.90 765.43 666.08 268.20 1,599.44	8,585.17 19.63 579.70 441.73 1,883.81	23,735.15 19.63 2,203.57 1,771.87 4,388.45	12,726.44 23.23 1,365.54 1,265.87 3,884.98	17,353.66 23.23 2,562.70 1,792.61 6,108.83
4	Total - (a to f)	12,007.05	11,938.30	32,903.59	20,334.54	29,213.18
5	Profit from operations before other income, finance cost and Exceptional items (1) - (2)	1,746.69	955.25	2,623.26	(1,882.19)	(4,980.52)
6	Other Income	0.60	4.81	101.43	21.76	161.89
7	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3)+(4)	1,747.29	960.06	2,724.69	(1,860.43)	(4,818.63)
8	Finance costs	433.45	422.87	1,280.87	2,187.48	2,426.34
9	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5)+(6)	1,313.84	537.19	1,443.81	(4,047.91)	(7,244.97)
10	Exceptional items	1,313.84	537.19	1,443.81	(4,047.91)	(7,244.97)
11	Profit / (Losses) from ordinary activities before tax (7)+(8)	474.00	26.00	500.00	664.00	433.91
12	Tax Expenses	839.84	511.19	943.81	(3,383.91)	(7,678.88)
13	Net Profit / (Loss) from ordinary activities after tax (9)-(10)	839.84	511.19	943.81	(3,383.91)	10,211.37
14	Extraordinary items (net of tax expenses Rs. ... in lakhs)					
15	Net Profit / (Loss) for the period (11) -(12)	839.84	511.19	943.81	(3,383.91)	2,532.49
16	Share of profit / (loss) of associates*					
17	Minority Interest*					
18	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)*	846.52	846.52	846.52	1,001.52	1,001.52
19.i	Paid-up equity share capital Rs.10/- per share					
19.ii	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	9.92	6.00	10.53	(33.79)	25.29
19.i	Earning Per Share (before extraordinary items) (of Rs.... / each) (not annualised)					
19.ii	Earning Per Share (after extraordinary items) (of Rs.... / each) (not annualised)					
19.i	(a) Basic					
19.ii	(b) Diluted					



A PARTICULARS OF SHARE HOLDING						
1	Public Shareholding - Number of Shares - Percentage of Shareholding	3,054,760 36.09	3,054,760 36.09	4,604,760 45.98	3,054,760 36.09	4,604,760 45.98
2	Promoters and Promoters Group Shareholding**					
a)	Pledged/Encumbered					
-	Number of Shares	-	-	-	-	-
-	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-
-	Percentage of Shares (as a % of the total share capital of the company)	-	-	-	-	-
b)	Non-encumbered					
-	Number of Shares	5,410,443	5,410,443	5,410,443	5,410,443	5,410,443
-	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100	100	100	100	100
-	Percentage of Shares (as a % of the total share capital of the company)	63.91	63.91	54.02	54.02	54.02


Particulars		3 Months ended 31-12-2013
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	4
	Disposed of during the quarter	4
	Remaining unresolved at the end of the quarter	Nil

Notes:

- The above results were reviewed by the Audit Committee on 11th February, 2014 and taken on record by the Board of Directors at its meeting held on 11th February, 2014 and "Limited Review" of the same has been carried out by the Statutory Auditors of the company.
- Earnings per Share has been calculated on the basis of weighted average number of Equity Shares.
- The Company's business activity falls within a single primary business segment. Hence segment reporting is not applicable.
- Figures of previous periods have been regrouped / rearranged wherever necessary.

By Order of the Board
For SMS Pharmaceuticals Limited

Ramesh Babu Potluri
Ramesh Babu Potluri
Chairman & Managing Director



Place: Hyderabad
Date: 11-02-2014

Limited Review Report

To
The Board of Directors
SMS PHARMACEUTICALS LIMITED
Hyderabad.

We have reviewed the accompanying statement of unaudited financial results of M/s. SMS PHARMACEUTICALS LIMITED for the quarter ended 31st December, 2013 except for the disclosures regarding 'public shareholding' and 'promoter Group Shareholding' which has been traced from disclosures made by the management and have not been reviewed by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 11-02-2014.

For RAMBABU & CO.,
Chartered Accountants
Firm Reg.No.0029765



GVL PRASAD
Partner
M. No. 026548

